Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Matrix metalloproteinases (MMPs) fulfill diverse important molecular functions and play pivotal roles in development, tissue morphogenesis, repair, aging, and inflammatory processes. MMPs are also important disease modulating factors, such as cancer, cardiovascular disease, rheumatoid arthritis or macular degeneration. Functional genetic variants have been described to fine-tune MMP activities at the gene transcriptional level and have been associated with increased genetic risk of e.g. arteriosclerosis or cancer. MMPs are also assumed to play a major role in the remodeling of the extracellular matrix (ECM) in the optic nerve head during glaucomatous optic neuropathy. MMP-1, MMP-3 and MMP-9 have been shown to be up-regulated in a variety of animal models of glaucoma. Here, we study three promoter SNPs within the genes encoding three members of the MMP family. By assessing the prevalence of genetic variants associated with either increased/decreased enzyme activity, we will (i) estimate their contribution to the genetic risk of developing primary open angle glaucoma (POAG) and (ii) investigate the potential role of MMPs in the functional pathology of POAG.
| Condition | Intervention |
|---|---|
|
Glaucoma |
Procedure: Blood Sample |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma? |
- Genotyping results and putatively associated odds with occurence of primary open angle glaucoma. [ Time Frame: 15 minutes ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 400 |
| Study Start Date: | November 2005 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1
Patients with primary open angle glaucoma
|
Procedure: Blood Sample
A single venous blood sample will be taken (10 ml).
|
|
2
Age- and sex-matched control subjects
|
Procedure: Blood Sample
A single venous blood sample will be taken (10 ml).
|
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Men and women older than 39 years
- Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)
- Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)
Exclusion Criteria:
- Exfoliation glaucoma, pigmentary glaucoma
- History of acute angle closure
Contacts and Locations| Austria | |
| Department of Clinical Pharmacology | |
| Vienna, Austria, 1090 | |
| Principal Investigator: | Gabriele Fuchsjaeger-Mayrl, M.D. | Department of Clinical Pharmacology, Medical University of Vienna |
More Information
No publications provided
| Responsible Party: | Gabriele Fuchsjaeger-Mayrl, Department of Clinical Pharmacology, Medical University of Vienna |
| ClinicalTrials.gov Identifier: | NCT00312403 History of Changes |
| Other Study ID Numbers: | OPHT-300505 |
| Study First Received: | April 6, 2006 |
| Last Updated: | January 14, 2010 |
| Health Authority: | Austria: Federal Ministry for Health and Women |
Keywords provided by Medical University of Vienna:
|
Glaucoma Gene Polymorphism Metalloproteinase |
Additional relevant MeSH terms:
|
Glaucoma Glaucoma, Open-Angle Ocular Hypertension Eye Diseases |
ClinicalTrials.gov processed this record on June 17, 2013